List of Excipients in Branded Drug LEXISCAN

« Back to Dashboard

Lexiscan Excipient Strategy and Commercial Opportunities in Regadenoson Injection

Last updated: September 24, 2026

Lexiscan is a ready-to-use, preservative-free regadenoson injection used for pharmacologic cardiac stress testing. Its commercial opportunity is concentrated in generic and differentiated sterile-injection products, including ready-to-administer presentations, prefilled syringes, improved stability, supply reliability, and hospital workflow integration. The principal formulation barrier is not a complex delivery system. It is the need to reproduce a low-dose, sterile, stable intravenous product with tightly controlled excipient composition and container-closure performance.

What is Lexiscan and how is it formulated?

Lexiscan contains regadenoson, an adenosine A2A receptor agonist. The FDA-approved product is administered as a rapid intravenous bolus at a 0.4 mg dose, followed by a saline flush. It is supplied as a single-dose injection containing 0.4 mg of regadenoson in 5 mL, equivalent to 0.08 mg/mL (FDA, 2023).

The labeled inactive ingredients are:

Excipient	Primary formulation function
Sodium phosphate monobasic monohydrate	Buffering and pH control
Sodium phosphate dibasic anhydrous	Buffering and pH control
Propylene glycol	Solvent and cosolvent
Edetate disodium	Chelation and metal-ion control
Water for injection	Sterile vehicle

The product has an acidic-to-neutral buffered formulation, with the labeled pH range generally reported at approximately 6.3 to 7.3. Lexiscan is a sterile, preservative-free product intended for single use. The formulation does not rely on antimicrobial preservatives because the vial is discarded after administration.

The excipient system is commercially significant because each component addresses a specific parenteral-development risk:

• The phosphate buffer controls pH during storage.
• Propylene glycol supports solubilization and formulation robustness.
• Edetate disodium reduces the risk of metal-catalyzed degradation.
• Water for injection provides the injectable vehicle without introducing additional formulation complexity.

What excipients are protected by Lexiscan patents?

The commercial Lexiscan formulation is likely protected primarily through product and formulation specifications rather than through a broad, durable excipient monopoly. Regadenoson composition-of-matter patents and early formulation patents have largely reached the end of their practical exclusivity period in the United States.

A generic applicant generally would not need to copy every inactive ingredient unless the reference product’s formulation is required to demonstrate pharmaceutical equivalence or the applicant relies on an abbreviated pathway that requires close formulation matching. An ANDA applicant may use different inactive ingredients if the product meets applicable pharmaceutical-equivalence, safety, quality, sterility, stability, and labeling requirements.

The most relevant IP categories are:

IP category	Relevance to a regadenoson generic
Regadenoson composition patents	Historically important, but likely expired or commercially weak for current U.S. entry
Use-of-regadenoson patents	May affect specific diagnostic or stress-testing methods
Formulation patents	Could cover concentration, buffer system, stability, or excipient ratios
Container-closure patents	Could affect prefilled syringes, cartridges, or specialized packaging
Manufacturing patents	May cover purification, crystallization, sterile filtration, or impurity control
Device patents	Relevant if the product is integrated with an injector or automated stress-testing platform

The FDA Orange Book is the controlling source for active U.S. patent listings and regulatory exclusivity associated with the reference product. Patent risk should be assessed separately from formulation similarity because a simple injectable may have limited formulation complexity but still face method-of-use or device-related claims (FDA, 2024a).

When does Lexiscan lose exclusivity?

Lexiscan’s principal U.S. commercial exclusivity has largely eroded. Regadenoson is no longer protected by the type of market exclusivity associated with a newly approved small-molecule drug. The key commercial question is whether any listed patent, regulatory exclusivity, or enforceable method-of-use claim blocks a specific generic presentation.

Lexiscan was approved by the FDA in 2008. The product is marketed by Astellas Pharma US, Inc. The original approval created a pathway for generic competition after expiration of applicable patents and exclusivities (FDA, 2008).

Exclusivity factor	Commercial assessment
New chemical entity exclusivity	Expired
Pediatric exclusivity	No current blocking significance identified
Orphan exclusivity	Not the principal basis of Lexiscan protection
Composition-of-matter protection	Historically important; not expected to block ordinary current entry
Formulation protection	Requires Orange Book and patent-family review
Method-of-use protection	Potentially relevant for specific labeled stress-imaging uses
Generic entry pathway	Primarily ANDA, subject to product-specific requirements

Exact patent expiration dates should be determined from the current Orange Book patent listing, patent prosecution records, and any terminal disclaimers. A patent expiration date alone does not establish freedom to launch if related method, formulation, process, or device patents remain enforceable.

Which companies are challenging Lexiscan?

Generic regadenoson injection products have entered or pursued the U.S. market through abbreviated regulatory pathways. Public FDA approval records identify generic versions of regadenoson injection, including products associated with manufacturers such as Teva Pharmaceuticals and other injectable-drug suppliers, depending on the product and approval date.

The competitive field is shaped by:

1. FDA-approved injectable generics.
2. Contract manufacturers with sterile-fill capacity.
3. Hospital and radiology distributors.
4. Suppliers offering prefilled or ready-to-administer formats.
5. International manufacturers seeking U.S. or regional approvals.

Paragraph IV litigation risk depends on whether an applicant certifies that a listed patent is invalid, unenforceable, or not infringed. For a mature product such as Lexiscan, Paragraph IV activity may be less important than ordinary ANDA approval, supply contracts, and hospital formulary conversion. A generic applicant can also submit a Section viii statement and omit a patented method of use if the remaining label supports a lawful non-infringing indication, subject to the precise patent claims and FDA labeling requirements (FDA, 2024b).

What formulation opportunities exist for regadenoson injection?

The strongest opportunities are incremental. A competing product does not need a new mechanism of action. It needs lower total cost, reduced preparation time, reliable supply, or better compatibility with nuclear-cardiology workflows.

1. Ready-to-use presentations

Lexiscan is already a ready-to-use injection, so a generic vial has limited differentiation. A prefilled syringe or ready-to-administer unit can reduce dose-drawing steps, minimize handling, and support standardized nuclear-stress protocols.

The commercial constraints include:

• Syringe-material compatibility.
• Extractables and leachables.
• Dose accuracy at low drug concentration.
• Needle and closure integrity.
• Labeling and human-factors review.
• Compatibility with automated injectors.
• Higher packaging cost.

2. Improved stability

A formulation developer could seek longer shelf life, broader storage conditions, or improved resistance to light and temperature excursions. The existing phosphate, propylene glycol, and edetate system provides a logical baseline for optimization.

Potential development targets include:

• Reduction of degradants during long-term storage.
• Improved stability after repeated temperature excursions.
• Lower particulate formation.
• Reduced interaction with glass, elastomer, or syringe materials.
• Compatibility with terminal sterilization only if product quality permits.

A stability improvement can support hospital inventory management but may be difficult to protect with a strong patent unless the formulation produces an unexpected technical result.

3. Alternative buffer systems

Phosphate is familiar and inexpensive, but alternative buffers could be evaluated for pH stability, precipitation risk, and compatibility with the container closure. Candidate systems would need to preserve regadenoson stability without creating new risks such as osmolality shifts, injection-site tolerability concerns, or interaction with the dosing line.

A non-phosphate formulation could create a differentiated patent position if it demonstrates superior impurity control or shelf life. The regulatory burden would increase if the formulation departs materially from the reference product.

4. Reduced excipient load

A simplified formulation may reduce manufacturing complexity and excipient-related tolerability concerns. Removing propylene glycol or edetate disodium would require evidence that solubility, stability, and impurity control remain acceptable.

This strategy is commercially relevant only if it improves manufacturing yield, reduces raw-material cost, or addresses a recognized clinical or regulatory concern. A lower excipient count alone is unlikely to command a premium.

5. Concentrated or lower-volume dosing

Lexiscan is administered as a fixed 0.4 mg dose. A lower-volume presentation could reduce injection and flush handling, but concentration changes create pharmaceutical-equivalence and dosing risks. A concentrated product could require a 505(b)(2) pathway or additional clinical and usability evidence rather than a straightforward ANDA, depending on the final formulation and presentation.

What manufacturing and IP barriers affect Lexiscan competitors?

Sterile manufacturing is the principal operational barrier. Regadenoson itself is a small molecule, but the product must meet injectable-drug standards for sterility, endotoxins, particulate matter, assay, impurities, content uniformity, container closure, and stability.

Key manufacturing risks include:

Risk	Commercial effect
Low-dose fill accuracy	Can create out-of-specification batches
Sterile filtration	Requires validated filter compatibility and adsorption control
Metal-ion contamination	Can accelerate degradation
Glass or elastomer interaction	May produce particles or leachables
Small-batch economics	Can increase unit cost
Supply interruption	Hospitals may switch suppliers quickly
Container-closure failure	Can trigger recalls and regulatory action

Regadenoson’s low dose creates a particular fill-finish challenge. The product concentration is low relative to many injectable drugs, making mixing uniformity and fill-volume control important. Edetate disodium can mitigate metal-catalyzed degradation, but it does not eliminate the need for control of raw-material quality and manufacturing equipment.

Process patents may have greater practical relevance outside the United States, where formulation and manufacturing claims can remain enforceable after composition patents expire. Geographic freedom-to-operate must therefore be assessed independently for the United States, Europe, Canada, Japan, and emerging markets.

How does Lexiscan compare with adenosine for commercial opportunity?

Regadenoson competes directly with adenosine for pharmacologic stress testing but has a different administration profile. Regadenoson is administered as a single fixed-dose bolus, while adenosine commonly requires weight-based administration by continuous infusion. This difference supports workflow and labor-saving value for Lexiscan-type products.

Factor	Regadenoson	Adenosine
Administration	Fixed-dose IV bolus	Continuous infusion
Preparation	Ready-to-use presentation	Infusion preparation often required
Workflow	Short bolus administration	Infusion pump and monitoring workflow
Formulation opportunity	Prefilled syringe, stability, packaging	Infusion bags, premixes, concentration options
Generic competition	Increasing	Established and broad
Differentiation	Convenience and protocol integration	Cost and availability

A regadenoson generic may support a premium over adenosine if it reduces preparation time and operational complexity. That premium is vulnerable when multiple suppliers offer interchangeable vials.

What is the FDA regulatory status of Lexiscan and generic regadenoson?

Lexiscan is an FDA-approved prescription injection for radionuclide myocardial perfusion imaging in patients unable to undergo adequate exercise stress. Generic regadenoson products generally follow the ANDA pathway when they match the reference product in dosage form, strength, route, and other relevant characteristics.

The major regulatory requirements include:

• Pharmaceutical equivalence.
• Bioequivalence or applicable waiver rationale.
• Sterility and endotoxin control.
• Stability data.
• Container-closure integrity.
• Extractables and leachables assessment.
• Drug-product impurity characterization.
• Inactive-ingredient justification.
• Manufacturing-process validation.

Because the product is administered intravenously and has a simple formulation, the central regulatory challenge is product quality rather than clinical differentiation. A substantially different excipient system, concentration, or delivery device may move the product toward a 505(b)(2) application.

What commercial opportunities exist beyond a standard generic?

The most credible opportunities are:

1. A lower-cost vial supplied under hospital and radiology-distributor contracts.
2. A prefilled syringe that removes dose-drawing steps.
3. A supply-secure product supported by dual manufacturing sites.
4. A regional product for markets with limited access to Lexiscan.
5. A co-packaged regimen with saline flush or stress-imaging workflow materials.
6. A contract-manufacturing platform for regadenoson and related diagnostic injectables.
7. A differentiated product with longer shelf life or improved temperature tolerance.

Revenue exposure is concentrated in nuclear cardiology and diagnostic imaging. Public company disclosures generally do not isolate Lexiscan revenue from broader portfolios, so product-level revenue estimates require prescription, purchasing, or channel data. Market access will depend more on contracting, shortage performance, and distributor coverage than on clinical differentiation.

How strong is the Lexiscan patent estate?

The estate is likely weak against a conventional, reference-matched generic but stronger against differentiated delivery systems or narrowly claimed formulations. The principal risks are:

• A listed formulation patent that remains active.
• A method-of-use patent covering a commercially important labeled use.
• A device or prefilled-syringe patent.
• Process patents affecting a specific manufacturing route.
• Patent rights in countries with later expiration dates than the United States.

A standard vial with substantially matching excipients is likely to face price competition rather than a durable patent barrier. A prefilled syringe or integrated injector may create a more defensible position, but it also introduces device, usability, and combination-product requirements.

Key Takeaways

• Lexiscan is a sterile, preservative-free regadenoson injection buffered with phosphate and formulated with propylene glycol, edetate disodium, and water for injection.
• The principal generic opportunity is a lower-cost, reliable injectable product rather than a radically new formulation.
• Prefilled syringes, supply-chain reliability, longer stability, and workflow integration offer the strongest commercial differentiation.
• The main technical barriers are sterile fill-finish, low-dose accuracy, impurity control, container compatibility, and stability.
• Conventional generic entry is primarily an ANDA opportunity; materially different formulations or devices may require a 505(b)(2) strategy.
• Composition-of-matter exclusivity is unlikely to be the main current barrier. Orange Book listings, method-of-use claims, formulation patents, and device rights remain relevant.
• Regadenoson competes with adenosine through fixed-dose bolus administration and reduced preparation burden.
• Product-level Lexiscan revenue is not generally disclosed separately by the sponsor, making hospital contracting and channel data more important than reported brand revenue.

FAQs About Lexiscan Excipient and Commercial Strategy

Can a generic regadenoson product use different excipients from Lexiscan?

Yes. A generic may use different inactive ingredients if it satisfies FDA requirements for pharmaceutical equivalence, safety, quality, stability, and regulatory comparability.

Is propylene glycol essential to the Lexiscan formulation?

Propylene glycol is a labeled component and likely supports solubility and formulation robustness, but a developer may evaluate alternative systems if the resulting product meets regulatory and stability requirements.

Is a prefilled Lexiscan syringe commercially attractive?

Yes, particularly where it reduces dose preparation, handling, and administration time. Its value is constrained by packaging cost, injector compatibility, and device-regulatory requirements.

Does Lexiscan require cold-chain distribution?

The product labeling governs storage requirements. A competing product may gain commercial value if it demonstrates broader temperature-excursion tolerance without compromising stability or sterility.

Can regadenoson be marketed for uses outside the Lexiscan label?

A company may pursue additional indications through an appropriate FDA pathway, but method-of-use patents, clinical evidence, labeling restrictions, and promotional controls must be assessed separately.

References

1. U.S. Food and Drug Administration. (2008). Lexiscan (regadenoson) injection: Original approval materials. FDA.

2. U.S. Food and Drug Administration. (2023). Lexiscan (regadenoson) injection prescribing information. Astellas Pharma US, Inc.

3. U.S. Food and Drug Administration. (2024a). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

4. U.S. Food and Drug Administration. (2024b). Abbreviated new drug application approvals and labeling requirements. FDA.